Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institutes of Health, Berlin, Germany.
Division of Molecular Diagnostics, Department of Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
Adv Exp Med Biol. 2019;1139:23-40. doi: 10.1007/978-3-030-14366-4_2.
Current systemic cancer treatment in head and neck squamous cell carcinoma (HNSCC) is moving toward more personalized approaches such as de-escalation protocols human-papilloma-virus dependent HNSCC or application of checkpoint inhibitors. However, these treatments have been challenged by cancer stem cells (CSC), a small population within the bulk tumor, which are leading to treatment failure, tumor recurrence, or metastases. This review will give an overview of the characteristics of HNSCC-CSC. Specifically, the mechanisms by which HNSCC-CSC induce tumor initiation, progression, recurrence, or metastasis will be discussed. Although evidence-based treatment options targeting HNSCC-CSC specifically are still being sought for, they warrant a promise for additional and sustainable treatment options where for HNSCC patients where others have failed.
目前,头颈部鳞状细胞癌(HNSCC)的全身癌症治疗正朝着更加个体化的方法发展,例如依赖人乳头瘤病毒的 HNSCC 的降级方案或应用检查点抑制剂。然而,这些治疗方法受到了肿瘤内一小部分癌症干细胞(CSC)的挑战,这导致了治疗失败、肿瘤复发或转移。这篇综述将概述 HNSCC-CSC 的特征。具体来说,将讨论 HNSCC-CSC 诱导肿瘤起始、进展、复发或转移的机制。尽管仍在寻求针对 HNSCC-CSC 的循证治疗选择,但它们为其他治疗方法失败的 HNSCC 患者提供了额外和可持续的治疗选择的希望。